秦冲

秦冲

博士

教授

博士生导师

科室：

药物合成

办公电话：

电子邮箱：

qc@ouc.edu.cn

联系地址：

青岛市崂山区香港东路23号中国海洋大学浮山校区研究院C303

研究方向：

1.基于靶向蛋白降解策略的新药发现

2.去势抵抗性前列腺癌治疗药物研究

3. 海洋天然活性物质的结构多样性修饰及成药性优化

个人简介

筑峰三层次教授，博士生导师，青岛海洋生物医药研究院副院长。主持国家高层次青年人才项目（2021）、国家重点研发计划青年科学家项目（2022）、国家自然基金青年基金（2021）、山东省“泰山学者”特聘专家（2025）、青年专家（2020）、山东省自然基金优秀青年基金（2021）等研究项目，获北京市自然科学奖一等奖（2019），青岛市自然科学一等奖（2025）。近年来在 J. Am. Chem. Soc.、Angew. Chem. Int. Ed.、J. Med. Chem. 等杂志发表学术论文三十余篇。

教育背景

2010.09~2015.07

北京大学

药物化学

博士 （导师：焦宁教授）

2006.09~2010.06

中国农业大学

应用化学

学士

工作经历

2019.09至今

中国海洋大学

教授

2016.01~2019.09

美国密歇根大学

博士后

荣誉奖励

青岛市自然科学一等奖（2025）

北京市自然科学奖一等奖（2019）

主讲《高等药物化学》研究生课程获教育部“拓金计划”示范课程（2022）、山东省研究生教育优质课程（2021）

北京大学学生五四奖章（2014）

课题组主页（The Qin Group @OUC）: http://qin.qdmbri.com/

ResearchGate:https://www.researchgate.net/profile/Chong-Qin-7

代表性论文

1)        Xiao Wang, Zhiyao Zhuang, Chengwei Zhang, Bowen Zhang, Wei Zhan, Yifan Wang, Zhaojuan Liu, Shanwen Yuan, Wenjia Niu, Qi He, Yanqing Tian, Ximing Xu*, Senbiao Fang*, Chong Qin*. MolGlueDB: an online database of molecular glues. Nucleic Acids Res.2026, 54, D1510.

2)        Xiao Wang, Ling Ge, Yawei Yu, Tengjiang Zhong, Weitong Hu, Sai Zhang, Xuan Chen, Miaoyuan Yang, Xinxin Zhang, Zhuoyue Li, Zhiyao Zhuang, Siqi Zhang, Xiaolin Jiang, Tao Wang, Huimin Chen, Senbiao Fang, Jianqing Gao*, and Chong Qin*. Discovery of an Androgen Receptor Degrader Featuring a Pyridazinyl Glutarimide CRBN-Binding Motif for Transdermal Treatment of Androgenetic Alopecia. J. Med. Chem.2026, 69, 13028-13054.

3)        Qibang Sui, Dan Wang, Hui Hou, Chen Shi, Xiaoying Cai, Yuanyang Zhou, Rongrong Cui, Manjia Li, Jia Liu, Dan Teng, Chong Qin*, Sulin Zhang*, and Mingyue Zheng*. Structure-Guided Discovery of Potent, Selective, and Orally Bioavailable Werner Syndrome RecQ Helicase Inhibitors for the Treatment of Microsatellite Instability-High Tumors. J. Med. Chem.2026, 69, DOI: 10.1021/acs.jmedchem.6c00331.

4)        Xiaolei Meng, Xiaolin Hu, Shan Gao, Wenrui Jia, Sai Zhang, Siqi Zhang, Xiao Wang, Shumin Ma, and Chong Qin*. PSMA-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer. J. Med. Chem.2025, 68, 10139-10155.

5)        Zhaojuan Liu, Heping Zheng, Yanqing Tian, Zhuoyue Li, Sai Zhang, Siqi Zhang, Shumin Ma*, Xiao Wang*, and Chong Qin*. ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer. J. Med. Chem.2025, 68, 20103-20129.

6)        Yan Lv, Gaoxin Dai, Bowen Zhang, Chang Liu, Yiming Chen, Ling Ge, Sai Zhang, Siqi Zhang, Mengjun Ma*, Shumin Ma*, and Chong Qin*. Discovery of LYA914, An Orally Bioavailable PROTAC Degrader Targeting the DNA Binding Domain of the Androgen Receptor for the Treatment of CRPC. J. Med. Chem. 2025, 68, 16593-16612.

7)        Bowen Zhang, Shan Gao, Tingting Wu, Yan Ma, Senbiao Fang, Mengyan Rong, Wenrui Jia, Sai Zhang, Hui Hou, Xiao Wang, Siqi Zhang, and Chong Qin*. Rational Design of Dual Degraders by Incorporating Molecular Glue Structural Features into PROTAC Degraders. J. Med. Chem.2025, 68, 10268-10298.

8)        Mengjun Ma, Mengyao Li, Chengwei Zhang, Zixuan Yang, Xiaoyu Chen, Penghui Lu, Shuangshuang Nie, Siqi Zhang*, Shumin Ma*, and Chong Qin*. Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer. J. Med. Chem.2024, 67, 17290-17318.

9)        Yan Lv+, Zixuan Yang+, Yiming Chen+, Xuepei Ma, Mengqi Guo, Chengwei Zhang, Xiaolin Jiang, Chengli Wang, Zhuoyue Li, Zhengfu Tai, Xiao Wang, Siqi Zhang*, Shumin Ma*, Chong Qin*. A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.J. Med. Chem.2024, 2487-2511. (IF: 8.039).

10)    Simin Sun+, Zhuoyue Li+, Chao Huang, Jinyu Liu, Qixin Yu, Xiaolin Jiang, Kairui Yue, Jianchun Zhao, Tongqiang Xu, Yankai Liu, Xiaoyang Li*, Chong Qin*, Yuqi Jiang*. Discovery of Novel 2,3-Dihydro-1H-indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon as a Potential Therapy for Colitis. J. Med. Chem.2023, 66, 16141–16167. (IF: 8.039).

11)    Zhuoyue Li+, Yiming Chen+, Xiaolin Jiang+, Penghui Lu, Chengli Wang, Zhimin Li, Xinyue Yu, Zixuan Yang, Shumin Ma, Shanshan Du, Zhengfu Tai, Xiaoyang Li*, Siqi Zhang*, Yuqi Jiang*, Chong Qin*. Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis. J. Med. Chem.2023, 66, 12966–12989. (IF: 8.039).

12)    Bowen Zhang+, Chang Liu+, Zhenqian Yang+, Sai Zhang+, Xiaolin Hu, Baohu Li, Mei Mao, Xiao Wang, Zhuoyue Li, Shumin Ma, Siqi Zhang, and Chong Qin*. Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer.J. Med. Chem.2023, 66, 11158-11186. (IF: 8.039)

13)    Siqi Zhang+, Xiaolei Meng+, Sai Zhang+, Baohu Li, Wencong Jin, Chengwei Zhang, Zhaojuan Liu, Xiaolin Hu, Ling Ge, Zhonghao Yu, Zhuoyue Li, Shumin Ma, Xiao Wang, Liming Li, Chong Qin*. Design, Synthesis and Biological Evaluation of Androgen Receptor (AR) Antagonist-Heat Shock Protein 90 (Hsp90) Inhibitor Conjugates for Targeted Therapy of Castration-Resistant Prostate Cancer. J. Med. Chem.2023, 66, 4784–4801. (IF: 8.039)

14)    Liming Li+*, Heping Zheng+, Xuepei Ma, Jie Bai, Shumin Ma, Zhuoyue Li, Chong Qin*. Inhibition of Astrocytic Carbohydrate Sulfotransferase 15 Promotes Nerve Repair After Spinal Cord Injury via Mitigation of CSPG Mediated Axonal Inhibition. Cell. Mol. Neurobiol.2023, 43, 2925–2937. (IF: 4.231)

15)    Qiang Wang, Baohu Li, Wenkai Zhang, Zhuoyue Li, Bo Jiang*, Sichuan Hou*, Shumin Ma*, Chong Qin*, Lethal Activity of BRD4 PROTAC Degrader QCA570 Against Bladder Cancer Cells. Front. Chem.2023, doi.org/10.3389/fchem.2023.1121724. (IF: 5.545)

16)    Ruxuan Wang, Tengjiang Zhong, Qiong Bian, Sai Zhang, Xiaolu Ma, Liming Li, Yihua Xu, Yueting Gu, Anran Yuan, Weitong Hu, Chong Qin*, Jianqing Gao*, PROTAC Degraders of Androgen Receptor-Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration. Small Methods.2023, 7, 2201293. (IF: 14.188)

17)    Chong Qin and Ning Jiao*, Iron-Facilitated Direct Oxidative C−H Transformation of Allylarenes or Alkenes to Alkenyl Nitriles. J. Am. Chem. Soc.2010, 132, 15893-15895;

18)    Chong Qin, Wang Zhou, Feng Chen, Yang Ou and Ning Jiao*, Iron-catalyzed C-H and C-C Bond Cleavage: A Direct Approach to Amides from Simple Hydrocarbon Molecules, Angew. Chem. Int. Ed. 2011, 50, 12595-12599;

19)    Chong Qin, Tao Shen, Conghui Tang and Ning Jiao*, FeCl2-promoted Unactivated C-C Bond Cleavage of Alkylarenes and Polystyrene: Direct Synthesis of Versatile Arylamines, Angew. Chem. Int. Ed.2012, 51, 6971-6975;

20)    Chong Qin, Peng Feng, Yang Ou, Tao Shen, Teng Wang and Ning Jiao*, Highly Selective Csp2-Csp Bond Cleavage: The Nitrogenation of Alkynes to Amides. Angew. Chem. Int. Ed. 2013, 52, 7850-7854;

21)    Chong Qin,+ Yijin Su,+ Xiaodong Shi and Ning Jiao*, Splitting a Substrate into Three Parts: Gold-Catalyzed Nitrogenation of Alkynes by C-C and C≡C Bond Cleavage. Angew. Chem. Int. Ed. 2016, 55, 350-354;

22)    Chong Qin,+Yang Hu,+ Bing Zhou,+... Shaomeng Wang*, Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J. Med. Chem.2018, 61, 6685–6704;

项目课题

1. 创新药物研发国家科技重大专项课题（2026ZD1806902），2026.5-2030.4，课题负责人；

2. 山东省“泰山学者”特聘专家，200万，2025.1-2029.12，主持；

3. 国家海外优青，300万，2022.1-2024.12，主持；

4. 国家重点研发计划青年科学家项目（2022YFC2804400），200万，2022.11-2025.10，主持；

5. 国家自然科学基金青年基金（22107095），30万，2022.1-2024.12，主持；

6. 山东省“泰山学者”青年专家（tsqn201909171），100万，2020.01-2024.12，主持；

7. 山东省自然科学基金优秀青年基金（22107095），40万，2022.1-2024.12，主持。